NL-OMON42002已完成不适用
A randomized, open-label, single-dose parallel-group trial to determine the pharmacokinetics and safety of GP2017 following a single subcutaneous injection by an autoinjector or by a pre-filled syringe in healthy male subjects - GP2017 biosimilar study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Hexal AG
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- healthy male volunteers
- •- age 18 - 55 inclusive
- •- BMI between 18.0 and 49.9 kilograms/meter2
- •- weight between 50.0 and 140.0 kg
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 12 weeks from the start of the study.
研究者
相似试验
已完成
不适用
A randomized, open-label, single dose, parallel study to evaluate the pharmacokinetics dose proportionality of GLA5PR GLARS-NF1 tablet in healthy male volunteersEndocrine, nutritional and metabolic diseaseKCT0001312GL PharmTech40
进行中（未招募）
不适用
Investigation of the ability of MRI to show changes in the nose after treatment of patients with Vicks® Sinex® Micromist®EUCTR2011-002443-10-GBProcter & Gamble Technical Centres Ltd., UK20
进行中（未招募）
1 期
An open-labeled, randomized, two-dose, parallel group trial of ofatumumab, a fully human monoclonal anti-CD20 antibody, in combination with fludarabine and cyclophosphamide, in patients with previously untreated B-cell Chronic Lymphocytic Leukemia - Ofatumumab with fludarabine and cyclophosphamide in B-CLL patientsEUCTR2007-000243-10-GBGlaxo SmithKline Research and Development Limited
进行中（未招募）
不适用
An open-labeled, randomized, two-dose, parallel group trial of ofatumumab, a fully human monoclonal anti-CD20 antibody, in combination with CHOP, in patients with previously untreated Follicular Lymphoma - Ofatumumab with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) in FL patientsEUCTR2007-000244-27-DEGlaxoSmithKline Research and Development Limited56
进行中（未招募）
不适用
An open-labeled, randomized, two-dose, parallel group trial of ofatumumab, a fully human monoclonal anti-CD20 antibody, in combination with fludarabine and cyclophosphamide, in patients with previously untreated B-cell Chronic Lymphocytic Leukemia - Ofatumumab with fludarabine and cyclophosphamide in B-CLL patientsEUCTR2007-000243-10-DEGlaxo SmithKline Research and Development Limited56